{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:03:34Z","timestamp":1793250214527,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.tcm.2019.11.001","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T03:01:19Z","timestamp":1574218879000},"page":"472-478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model"],"prefix":"10.1016","volume":"30","author":[{"given":"Milena","family":"Aksentijevich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundus S.","family":"Lateef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Anzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit K.","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal N.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.tcm.2019.11.001_bib0001","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 Update: a report from the american heart association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.tcm.2019.11.001_bib0002","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"N Engl J Med"},{"issue":"0","key":"10.1016\/j.tcm.2019.11.001_bib0003","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease","volume":"0","author":"Arnett","year":"2019","journal-title":"Circulation."},{"issue":"2","key":"10.1016\/j.tcm.2019.11.001_bib0004","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.tcm.2019.11.001_bib0005","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3389\/fimmu.2018.01234","article-title":"Potential immunological links between psoriasis and cardiovascular disease","volume":"9","author":"Sajja","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.tcm.2019.11.001_bib0006","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","article-title":"Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences","volume":"9","author":"Boehncke","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.tcm.2019.11.001_bib0007","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3899\/jrheum.190114","article-title":"Cardiovascular diseases in psoriasis and psoriatic arthritis","volume":"95","author":"Eder","year":"2019","journal-title":"J Rheumatol Suppl"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.001_bib0008","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.tcm.2019.11.001_bib0009","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tcm.2019.11.001_bib0010","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1161\/CIRCRESAHA.114.303312","article-title":"Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis","volume":"114","author":"Knight","year":"2014","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.tcm.2019.11.001_bib0011","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1210\/jc.2006-2545","article-title":"Innate immunity modulates adipokines in humans","volume":"92","author":"Anderson","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.tcm.2019.11.001_bib0012","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.atherosclerosis.2012.02.032","article-title":"Inflammation modulates human HDL composition and function in vivo","volume":"222","author":"de la Llera Moya","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tcm.2019.11.001_bib0013","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1479-5876-10-124","article-title":"A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial","volume":"10","author":"Mehta","year":"2012","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.tcm.2019.11.001_bib0014","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db09-0367","article-title":"Experimental endotoxemia induces adipose inflammation and insulin resistance in humans","volume":"59","author":"Mehta","year":"2010","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.001_bib0015","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/ATVBAHA.118.312246","article-title":"Inflammasome signaling and impaired vascular health in psoriasis","volume":"39","author":"Garshick","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.tcm.2019.11.001_bib0016","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1161\/ATVBAHA.115.306460","article-title":"Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET\/CT and neutrophil activation in a prospective observational study","volume":"35","author":"Naik","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.tcm.2019.11.001_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacbts.2018.10.008","article-title":"Neutrophil subsets, platelets, and vascular disease in psoriasis","volume":"4","author":"Teague","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.tcm.2019.11.001_bib0018","article-title":"Cells of myeloid origin partly mediate the association between psoriasis severity and coronary plaque","author":"Teague","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.001_bib0019","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cels.2015.09.007","article-title":"The biomarker GlycA is associated with chronic inflammation and predicts long-term risk of severe infection","volume":"1","author":"Ritchie","year":"2015","journal-title":"Cell Syst"},{"issue":"11","key":"10.1016\/j.tcm.2019.11.001_bib0020","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/CIRCRESAHA.116.309637","article-title":"GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis","volume":"119","author":"Joshi","year":"2016","journal-title":"Circ Res"},{"issue":"12","key":"10.1016\/j.tcm.2019.11.001_bib0021","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jacc.2018.12.075","article-title":"Vascular inflammation in subclinical atherosclerosis detected by hybrid PET\/MRI","volume":"73","author":"Fernandez-Friera","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.tcm.2019.11.001_bib0022","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2012.06.068","article-title":"Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis","volume":"224","author":"Mehta","year":"2012","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.tcm.2019.11.001_bib0023","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1161\/CIRCRESAHA.118.313608","article-title":"Association between oxidation-modified lipoproteins and coronary plaque in psoriasis","volume":"123","author":"Sorokin","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.tcm.2019.11.001_bib0077","article-title":"Association between soluble lectinlike oxidized low-density lipoprotein receptor-1 and coronary artery disease in psoriasis","author":"Dey","year":"2019","journal-title":"JAMA Dermatol."},{"issue":"7","key":"10.1016\/j.tcm.2019.11.001_bib0024","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2337\/dc08-1795","article-title":"Low-grade chronic inflammation in the relationship between insulin sensitivity and cardiovascular disease (RISC) population: associations with insulin resistance and cardiometabolic risk profile","volume":"32","author":"de Rooij","year":"2009","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.tcm.2019.11.001_bib0025","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1194\/jlr.R300019-JLR200","article-title":"Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host","volume":"45","author":"Khovidhunkit","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.tcm.2019.11.001_bib0026","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/1479-5876-11-194","article-title":"Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis","volume":"11","author":"Mehta","year":"2013","journal-title":"J Transl Med"},{"issue":"10","key":"10.1016\/j.tcm.2019.11.001_bib0027","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.tcm.2019.11.001_bib0028","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.tcm.2019.11.001_bib0029","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and Beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.tcm.2019.11.001_bib0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.sder.2010.01.002","article-title":"Comorbidities in psoriasis patients","volume":"29","author":"Kim","year":"2010","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.tcm.2019.11.001_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2009.09281.x","article-title":"More than skin deep: atherosclerosis as a systemic manifestation of psoriasis","volume":"161","author":"Alexandroff","year":"2009","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.tcm.2019.11.001_bib0032","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1468-3083.2010.03947.x","article-title":"Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study","volume":"25","author":"Boehncke","year":"2011","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.001_bib0033","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exper Dermatol"},{"issue":"14","key":"10.1016\/j.tcm.2019.11.001_bib0034","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.001_bib0035","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.amjmed.2009.08.022","article-title":"Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis","volume":"123","author":"Kimball","year":"2010","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.tcm.2019.11.001_bib0036","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/archderm.143.12.1493","article-title":"The risk of mortality in patients with psoriasis: results from a population-based study","volume":"143","author":"Gelfand","year":"2007","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.tcm.2019.11.001_bib0037","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.tcm.2019.11.001_bib0038","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jamacardio.2017.1213","article-title":"Association between skin and aortic vascular inflammation in patients with psoriasis: a case-cohort study using positron emission tomography\/computed tomography","volume":"2","author":"Dey","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.tcm.2019.11.001_bib0039","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/CIRCULATIONAHA.116.026859","article-title":"Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study","volume":"136","author":"Lerman","year":"2017","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.tcm.2019.11.001_bib0040","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/jamadermatol.2016.2907","article-title":"Comparison of coronary artery calcium scores between patients with psoriasis and Type 2 diabetes","volume":"152","author":"Mansouri","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.tcm.2019.11.001_bib0041","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/annrheumdis-2012-201497","article-title":"The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone","volume":"72","author":"Eder","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.tcm.2019.11.001_bib0042","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000111512","article-title":"Association between psoriasis and the metabolic syndrome. A Cross-Sectional Study","volume":"216","author":"Cohen","year":"2008","journal-title":"Dermatology."},{"issue":"1","key":"10.1016\/j.tcm.2019.11.001_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mjd.2002.120568","article-title":"The immunologic basis for the treatment of psoriasis with new biologic agents","volume":"46","author":"Krueger","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.tcm.2019.11.001_bib0044","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.tcm.2019.11.001_bib0045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97179","article-title":"Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis","volume":"3","author":"Baumer","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.001_bib0046","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jaad.2013.06.019","article-title":"Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study","volume":"69","author":"Jokai","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.tcm.2019.11.001_bib0047","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/art.38227","article-title":"Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women","volume":"66","author":"Wu","year":"2014","journal-title":"Arthr Rheumatol (Hoboken, NJ)"},{"issue":"39","key":"10.1016\/j.tcm.2019.11.001_bib0048","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1093\/eurheartj\/ehv339","article-title":"Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis","volume":"36","author":"Salahuddin","year":"2015","journal-title":"Eur Heart J"},{"issue":"3 Pt 1","key":"10.1016\/j.tcm.2019.11.001_bib0049","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.tcm.2019.11.001_bib0050","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr Diab"},{"key":"10.1016\/j.tcm.2019.11.001_bib0051","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12967-014-0258-2","article-title":"Characterization of immune cells in psoriatic adipose tissue","volume":"12","author":"Rose","year":"2014","journal-title":"J Transl Med"},{"issue":"6","key":"10.1016\/j.tcm.2019.11.001_bib0052","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jaad.2015.02.1095","article-title":"Psoriasis and risk of diabetes-associated microvascular and macrovascular complications","volume":"72","author":"Armstrong","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.001_bib0053","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jaad.2015.01.004","article-title":"Patients with psoriasis are insulin resistant","volume":"72","author":"Gyldenlove","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2 Pt 2","key":"10.1016\/j.tcm.2019.11.001_bib0054","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jcmg.2017.08.014","article-title":"Visceral adiposity in psoriasis is associated with vascular inflammation by (18)F-Fluorodeoxyglucose positron-emission tomography\/computed tomography beyond cardiometabolic disease risk Factors in an observational cohort study","volume":"11","author":"Rivers","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"suppl_1","key":"10.1016\/j.tcm.2019.11.001_bib0055","first-page":"A549","article-title":"Abstract 549: visceral adipose tissue associates with coronary plaque burden beyond cardiovascular risk factors in psoriasis","volume":"37","author":"Rivers Joshua","year":"2017","journal-title":"Arteriosc Thromb Vascul Biol"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.001_bib0056","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jamasurg.2016.4610","article-title":"Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery","volume":"152","author":"Egeberg","year":"2017","journal-title":"JAMA Surgery"},{"key":"10.1016\/j.tcm.2019.11.001_bib0057","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.3389\/fimmu.2019.01807","article-title":"Psoriasis: obesity and fatty acids","volume":"10","author":"Kunz","year":"2019","journal-title":"Front Immunol"},{"issue":"18","key":"10.1016\/j.tcm.2019.11.001_bib0058","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","article-title":"Psoriasis","volume":"352","author":"Schon","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tcm.2019.11.001_bib0059","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jdv.12768","article-title":"Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort","volume":"29","author":"Ahlehoff","year":"2015","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"1","key":"10.1016\/j.tcm.2019.11.001_bib0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0190-9622(92)70012-5","article-title":"Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis.","volume":"26","author":"Christophers","year":"1992","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.tcm.2019.11.001_bib0061","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaad.2004.06.017","article-title":"Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis","volume":"52","author":"Prodanovich","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.tcm.2019.11.001_bib0062","first-page":"116","article-title":"Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial","volume":"158","author":"Flytstrom","year":"2008","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.tcm.2019.11.001_bib0063","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.tcm.2019.11.001_bib0064","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu","year":"2012","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.tcm.2019.11.001_bib0065","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2133.2008.08628.x","article-title":"Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis","volume":"159","author":"Strober","year":"2008","journal-title":"Br J Dermatol"},{"issue":"24","key":"10.1016\/j.tcm.2019.11.001_bib0066","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.2011.878","article-title":"Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis","volume":"305","author":"Solomon","year":"2011","journal-title":"Jama"},{"issue":"10","key":"10.1016\/j.tcm.2019.11.001_bib0067","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamadermatol.2016.1984","article-title":"Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis","volume":"152","author":"Hjuler","year":"2016","journal-title":"JAMA Dermat"},{"issue":"5","key":"10.1016\/j.tcm.2019.11.001_bib0068","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/jdv.13152","article-title":"Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study","volume":"30","author":"Ahlehoff","year":"2016","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.001_bib0069","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.tcm.2019.11.001_bib0070","article-title":"Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index","author":"Elnabawi","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.tcm.2019.11.001_bib0071","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jid.2017.02.977","article-title":"TNF-alpha antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study","volume":"137","author":"Bissonnette","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.tcm.2019.11.001_bib0072","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial","volume":"11","author":"Mehta","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"issue":"9","key":"10.1016\/j.tcm.2019.11.001_bib0073","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.006283","article-title":"Lowering Interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor-a antagonism or cyclosporine in psoriasis","volume":"10","author":"Ikonomidis","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.tcm.2019.11.001_bib0074","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.tcm.2019.11.001_bib0075","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jid.2018.09.021","article-title":"Antagonization of IL-17A attenuates skin inflammation and vascular dysfunction in mouse models of psoriasis","volume":"139","author":"Schuler","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.tcm.2019.11.001_bib0076","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J Invest Dermatol"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173819301513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173819301513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:00:06Z","timestamp":1760936406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173819301513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1050173819301513"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2019.11.001","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2019.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}